Association between the haemoglobin glycation index (HGI) and clinical outcomes in patients with acute decompensated heart failure

Weimeng Cheng,Rong Huang,Yue Pu,Tianyue Li,Xue Bao,Jianzhou Chen,Guannan Li,Han Wu,Zhonghai Wei

DOI: https://doi.org/10.1080/07853890.2024.2330615

IF: 5.348

2024-03-22

Annals of Medicine

Abstract:Background A growing number of studies show that people with similar blood glucose levels have different levels of glycosylated haemoglobin (HbA1c), and relying only on HbA1c may lead to clinical decision-making errors. The haemoglobin glycation index (HGI) quantifies the difference in HbA1c among individuals and is strongly linked to the risk of cardiovascular disease. However, the connection between this phenomenon and the poor outcomes of patients with acute decompensated heart failure (ADHF) is currently unknown.

medicine, general & internal

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the relationship between the hemoglobin glycation index (HGI) and the clinical outcomes of patients with acute decompensated heart failure (ADHF). Specifically, the study aims to answer the following questions:

1. **Relationship between HGI and all - cause mortality**: Is a high HGI associated with a lower all - cause mortality?
2. **Relationship between HGI and cardiovascular mortality**: Is a high HGI associated with a lower cardiovascular mortality?
3. **Relationship between HGI and major adverse cardiac events (MACE)**: Does HGI affect the occurrence of non - fatal myocardial infarction, non - fatal stroke or worsening of heart failure?

### Research background
Recent studies have shown that among populations with similar blood - glucose levels, there are significant differences in glycated hemoglobin (HbA1c) levels, and relying solely on HbA1c may lead to clinical decision - making errors. HGI quantifies the differences in HbA1c levels among individuals and is closely related to the risk of cardiovascular diseases. However, the relationship between HGI and adverse outcomes in patients with acute decompensated heart failure remains unclear.

### Method overview
This study is a retrospective single - center cohort study, including 1,531 ADHF patients hospitalized between September 2010 and January 2020. HGI was calculated by the following formulas:
\[ \text{Predicted HbA1c} = 0.024\times\text{fasting blood glucose (FPG)} (\text{mg/dl})+ 3.1 \]
\[ \text{HGI}=\text{observed HbA1c}-\text{predicted HbA1c} \]

The study endpoints included all - cause death, cardiovascular death and major adverse cardiac events (MACE). The researchers used a multivariable - adjusted Cox proportional - hazards model to evaluate the association between HGI and these clinical outcomes.

### Main results
- During the five - year follow - up period, 27.9% of the patients died of all - cause death, 15.6% died of cardiovascular death, and 55.4% experienced MACE.
- Restricted cubic spline analysis showed that an increase in HGI was associated with a linearly decreasing trend in the cumulative risk of all - cause death and cardiovascular death.
- The multivariable Cox proportional - hazards model showed that the highest tertile of HGI was associated with a lower incidence of all - cause death (adjusted hazard ratio [HR] = 0.720, 95% CI: 0.563 - 0.921, p = 0.009) and cardiovascular death (adjusted HR = 0.619, 95% CI: 0.445 - 0.861, p = 0.004).
- For every 1% increase in HGI, the all - cause death risk decreased by 12.5% and the cardiovascular death risk decreased by 20.8%.

### Conclusion
A high HGI is directly related to the reduction of all - cause death and cardiovascular death, but is not related to MACE. These findings may be helpful for the management of patients with acute decompensated heart failure.

### Key information
1. Recent studies have shown that significant differences between HbA1c and actual blood - glucose levels may lead to clinical decision - making errors.
2. The predictive ability of HGI may vary among different disease populations.

Through this study, the authors hope to provide clinicians with a new perspective to better manage and treat patients with acute decompensated heart failure.